Project Grant R44DK142547
Award Date 9/1/26
Completion Date 5/31/28
Dollars Obligated $1.5M
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New Haven, CT 06511, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $584,232 to Renovate Biosciences Inc. on September 25, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Renovate Biosciences will generate human livers from donor patient-specific cells using pigs as bio-incubators. Following technical validation, the work will establish a pathway for producing on-demand transplantation-ready hepatocytes for cellular therapies and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Delphi Stem, Inc. $306,863 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a framework for evaluating type 2 diabetes medication efficacy using patient-derived cellular models. The recipient will generate personalized islet-like aggregates from patient cells to predict drug responsiveness and tailor treatment regimens, with the goal of improving...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Merakris Therapeutics Inc. $2,219,008 on July 20, 2026, to conduct a Phase II clinical trial evaluating the efficacy and safety of MTX-001, a first-in-class biologic therapy, in treating diabetic foot ulcers. MTX-001 is a biologic with anti-inflammatory, antimicrobial, anti-proteolytic, and pro-growth functions. Preliminary Phase II results from treating venous leg ulcers demonstrated safety, an average 83 percent...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Halomine Inc. (doing business as Avantguard) $348,150 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and optimize Avantamine, a stabilized chloramine-based topical antiseptic for treatment of infected diabetic foot ulcers. The project will examine efficacy of Avantamine against bacteria found in diabetic foot ulcers using a porcine tissue...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Microvascular Tissues, Inc., $700,000 on September 17, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the effect of a local microvascular tissue graft treatment in rat models of diabetic peripheral neuropathy. Microvascular Tissues, Inc., will conduct preclinical research on MVASC, a novel human structural allograft consisting of lyophilized and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Rowan University $561,681 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on July 1, 2026. The award funds research evaluating combined electric field stimulation and nitric oxide therapy as a multi-targeted treatment for diabetic foot ulcers. The study develops bio-engineered approaches to address the complex pathology underlying diabetic foot ulcer formation—peripheral...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services, awarded Silq Technologies Corporation $320,965 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Silq will develop a zwitterion-treated ureteral stent designed to reduce device-related complications in patients with ureteral obstructions. The work encompasses three aims: developing the zwitterion-treated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Pittsburgh $530,328 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate biofilm-host defense mechanisms in diabetic wound healing. The research addresses how Staphylococcus aureus biofilm infections impair wound macrophage function, leading to chronic inflammation and poor healing outcomes in diabetic foot ulcers. The project...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Rush University Medical Center $749,087 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate sodium-independent mechanisms of edema in nephrotic syndrome. The project studies the role of circulating angiopoietin-like 4 (ANGPTL4), specifically its C-fragment, as a mediator of skin capillary endothelial permeability in nephrotic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded SFC Fluidics, Inc. $250,000 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop a phenolics depletion chip for insulin delivery patch pumps. The recipient will design and prototype a small, low-power electrochemical device that removes phenolic compounds (phenol and meta-cresol) from insulin formulations immediately prior to injection in...